Compare AbCellera Biologics Inc (ABCL) vs FirstEnergy Corp. (FE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs FirstEnergy Corp. — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while FirstEnergy Corp. trades at $48.17 (market cap $27.99B). The key difference: FirstEnergy Corp. is far larger — about 11.9× AbCellera Biologics Inc's market cap, and FirstEnergy Corp. pays a 3.84% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | FE | |
|---|---|---|
Market Cap | $2.35B | $27.99B |
Sector | Health | Utilities |
52-Week High | $8.12 | $51.91 |
52-Week Low | $2.78 | $39.89 |
Enterprise Value | $1.99B | $56.00B |
Dividend Yield | — | 3.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
FirstEnergy (FE) trades at $48.39, down 0.25% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $52.25. The company reported revenue of $15.09 billion in 2025, with net income of $1.02 billion, and recent earnings have mostly beaten expectations. Positive news highlights growth from data center demand and a $36 billion investment plan for grid upgrades.
The outlook is supported by earnings visibility and strategic investments, but risks include regulatory uncertainty and high debt levels. With no sell ratings from analysts and a dividend payout scheduled, FE presents a steady utility investment with moderate upside potential balanced by sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →
